The idea of combining glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist for reducing glycated hemoglobin A1c (HbA1c) and body weight has already been circulated for quite some time.1 Recently, a double-blind, randomized, phase 2 ...

Canagliflozin is the first sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes.1 Although canagliflozin offers benefits such as reductions in body weight, blood pressure, and risk for hypoglycemia,2 the US Food and Drug Administration (FDA) has included a ...

Oral delivery of therapeutic peptides has always been a challenging topic because protein will denature in the gastrointestinal tract, making it difficult to deliver the drug to the targeted site. Recently, a breakthrough has been made by Dr. Aroda and her PIONEER-1 trial research team, who demonstr...